T-cell dysfunctionality was partially overcome ex vivo with PD-1 and LAG-3 co-blockade in T-cells from non-small cell lung cancer (NSCLC) patients, which recovered proliferative and effector activities (Edwards et al, 2022; Zuazo et al, 2019). This evidence concerns the gene LAG3 and non-small cell lung carcinoma.